NCT02160925已完成不适用
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 125
- 试验地点
- 2
- 主要终点
- Correlation of preoperative 99mTc-sestamibi SPECT/CT findings with tumor histology following surgical resection.
研究概览
简要总结
The objective of this study is to investigate the utility of 99mTc-sestamibi SPECT/CT imaging for the diagnosis of renal oncocytomas.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of a solid enhancing cT1 renal mass detected on cross-sectional imaging
- •Scheduled to undergo surgery with either partial or radical nephrectomy
- •Age ≥18 years
排除标准
- •Pregnancy
- •Evidence of nodal or distant metastases
- •History of other malignancy with concern for renal metastasis
- •Known allergy to technetium or sestamibi
研究组 & 干预措施
Preoperative 99mTc-Sestamibi SPECT/CT
Experimental
干预措施: Preoperative 99mTc-Sestamibi SPECT/CT (Other)
结局指标
主要结局
Correlation of preoperative 99mTc-sestamibi SPECT/CT findings with tumor histology following surgical resection.
时间窗: Within 2 weeks of surgery
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
4 期
99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) PatientsThyroid CancerNCT03065218Medstar Health Research Institute4
Unknown
不适用
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) ThyroidPapillary Thyroid CancerNCT00984191Chulalongkorn University15
招募中
不适用
99mTc-CNDG SPECT/CT in Brain TumorsIntracranial TumorNCT06362304Peking Union Medical College Hospital30
进行中(未招募)
不适用
SPECT/CT for the Characterization of Renal MassesKidney NeoplasmRenal MassNCT03996850Jonsson Comprehensive Cancer Center102
终止
1 期
Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer PatientsBreast CancerNCT02024074Emory University1
